Tweetovi

Blokirali ste korisnika/cu @ThirdRockV

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ThirdRockV

  1. 29. sij
    Poništi
  2. proslijedio/la je Tweet
    29. sij

    We're excited to announce a new strategic research focus on regenerative medicine approaches for the inner ear, including a collaboration and option agreement with The Rockefeller University to license a novel series of small-molecule LATS inhibitors:

    Poništi
  3. 14. sij

    "The growth is where the real innovation is, and where you can make a real difference in the patients' lives." TRV partner Abbie Celniker and discussed the future of biotech investing and key areas of progress in the industry.

    Poništi
  4. 14. sij

    Partner Abbie Celniker live with at discussing innovation and the science and technologies we are excited about.

    Poništi
  5. proslijedio/la je Tweet
    Poništi
  6. 9. sij

    Congrats to on receiving FDA approval for AYVAKIT, the 1st approved precision therapy for GIST & the only highly active treatment for a specific mutation of GIST. What a great day for patients & their families awaiting new treatment options.

    Poništi
  7. proslijedio/la je Tweet
    9. sij

    Today, we received approval for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor () harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Learn more:

    Poništi
  8. proslijedio/la je Tweet
    30. pro 2019.

    We’re excited to announce a research collaboration with to identify small molecules designed to modulate genetic pathways associated with an indication in . Learn more about our partnership here:

    Poništi
  9. 19. pro 2019.

    ., a company translating insights in immunometabolism into novel treatments for immune-mediated diseases and cancer, announced a collaboration with today. Congrats to the team!

    Poništi
  10. proslijedio/la je Tweet
    18. pro 2019.

    We’re pleased to announce that we have filed a CTA in Europe for evaluation of NEO-PTC-01, a personal neoantigen-targeted T cell therapy candidate. We plan a Phase 1 trial in patients with metastatic melanoma who are refractory to checkpoint inhibitors.

    Poništi
  11. proslijedio/la je Tweet

    Congratulations to Thrive Earlier Detection for winning the BlueCross BlueShield (BCBS) Data Innovation Challenge! As the winner, they will use BCBS to find innovative ways to detect cancer earlier at a more cost-effective price.

    Poništi
  12. proslijedio/la je Tweet
    Poništi
  13. 26. stu 2019.

    Congrats to on receiving approval for Oxbryta - the first treatment that directly targets the root cause of disease. Great news for millions of patients around the world. Read more:

    Poništi
  14. 19. stu 2019.

    .’s approach combines biology and artificial intelligence with the aim of revolutionizing drug discovery. interviewed CEO on her career path and what’s next for the company.

    Poništi
  15. 15. stu 2019.

    Congratulations to , and for being named to the ’s 2019 Top Places to Work in Massachusetts!

    Poništi
  16. 11. stu 2019.

    Congratulations to all of ’s Fiercest Women in Life Sciences, including Cedilla Therapeutics CEO Sandra Glucksmann and CEO !

    Poništi
  17. 11. stu 2019.

    We’re proud of Barbara Weber and for being recognized among ’s 20 extraordinary women in biopharma R&D. Thank you for all you do for patients!

    Poništi
  18. 23. lis 2019.

    Pliant Therapeutics is focused on discovering and developing novel therapies for the treatment of fibrosis. Today they announced a partnership with to develop and commercialize NASH therapies. Congrats to the teams!

    Poništi
  19. 21. lis 2019.

    We are proud to have joined over 5,000 blood cancer survivors and supporters at . Thank you to for all you do!

    Poništi
  20. 21. lis 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·